Micron Biomedical Hires Eli Lilly Vet to Scale Needle-Free GLP-1s

ATLANTA, GA – October 28, 2026 — The race to replace the traditional syringe is accelerating. Micron Biomedical, an Atlanta-based clinical-stage biotechnology company, announced today the appointment of drug delivery industry veteran Anand Subramony, Ph.D., as Executive Vice President of Global Product Development and Combination Product Commercialization. The strategic hire signals a major inflection point for the company as it transitions from an early-stage vaccine platform into a commercial-scale player targeting high-value therapeutic markets, most notably the booming GLP-1 weight loss sector.

Dr. Subramony arrives with 27 years of experience in developing drug-device combination products across pharmaceutical giants including Eli Lilly, AstraZeneca, Novartis, and Johnson & Johnson's ALZA Corporation. Most recently, as Vice President of Delivery, Device and Connection Solutions at Eli Lilly, he built the company's early development organization and advanced new delivery technologies for incretin medicines—the class of drugs that includes blockbuster GLP-1 agonists.

"As demand for novel biologics that can be manufactured, stored, transported and self-administered without cold-chain and injection-related barriers of traditional injectable medicines expands beyond vaccines to areas including biosecurity measures, GLP-1s, and other combination products, Micron is committed to advancing an expanding pipeline of accessible and life-changing biotech innovations," said Steven Damon, CEO of Micron Biomedical. "Anand brings decades of experience turning innovative drug delivery technologies into successful medicines at Lilly and AstraZeneca, and his leadership, combined with our strong clinical evidence, solidified backing by government and industry partners and commercial-scale manufacturing facility, position Micron Biomedical to bring a new generation of treatments to the market at scale."

The Needle-Free Race for the Multi-Billion Dollar GLP-1 Market

Micron's proprietary technology utilizes dissolvable microscopic arrays—often referred to as microneedle patches—to administer biologics, peptides, and small molecules painlessly through the skin. The arrays create transient pores in the stratum corneum, allowing the drug to dissolve directly into the epidermis and dermis, which are rich in immune cells and capillaries. This method bypasses the gastrointestinal tract, preventing the degradation of sensitive peptide drugs and avoiding first-pass metabolism.

The addition of Dr. Subramony directly addresses the engineering and formulation challenges inherent in this delivery method. While microneedles have shown tremendous promise, achieving sufficient and consistent bioavailability for high-dose therapeutics like GLP-1 agonists remains a significant industry hurdle. Current GLP-1 drugs for obesity and diabetes often require weekly subcutaneous doses of several milligrams. Delivering such large quantities transdermally without drastically increasing the patch size or the frequency of application requires highly advanced formulation science.

During his tenure at Eli Lilly and AstraZeneca, Dr. Subramony led foundational device work for large-volume biologics and advanced an oral peptide GLP-1 program to clinical evaluation. His expertise in nanomedicine platforms and injection physiology will be critical as Micron attempts to disrupt a market currently dominated by traditional auto-injectors. While auto-injectors provide precise, high-dose delivery, they are heavily associated with needle phobia, generate significant biohazard sharps waste, and often require strict cold-chain storage.

Pharmaceutical formulation experts tracking the space note that if Micron can successfully formulate a thermostable, high-dose GLP-1 peptide into a dissolvable array, it could fundamentally alter patient compliance and market dynamics, offering a discreet, painless, and shelf-stable alternative to current blockbuster treatments.

Ending the Cold Chain: Reshaping Global Health Logistics

While the GLP-1 market offers massive commercial upside, Micron Biomedical's foundation rests on solving critical global health challenges. The company has garnered immense support from public health and philanthropic organizations aiming to eliminate the logistical nightmares of cold-chain dependencies in developing nations.

The Bill & Melinda Gates Foundation has been a cornerstone backer, providing a total of $43 million in grant funding to the company. This includes a recent $7.5 million grant in January 2025 to support manufacturing scale-up and a Phase 2 trial for a measles-rubella (MR) vaccine in infants, building upon an earlier $23.6 million grant designed to fund the mass production of needle-free MR vaccines. Clinical trials have already demonstrated the platform's viability; a Phase 1/2 study published in The Lancet showed that Micron's MR vaccine microarray technology was well-tolerated, safe, and elicited an immune response comparable to traditional subcutaneous injections in adults and children as young as nine months.

Beyond routine immunizations, the technology is increasingly viewed as a vital biosecurity asset. In July 2026, the National Institute of Allergy and Infectious Diseases (NIAID) awarded Micron a $4.5 million contract to develop the first dissolvable microarray medical countermeasure against Acute Radiation Syndrome (ARS). Designed for rapid, self-administered deployment in emergency scenarios, the technology incorporates a novel TLR5 agonist.

The company has also secured a $3.7 million award from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop needle-free vaccines against "Disease X," and a $2 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop broadly protective mRNA flu vaccines. Furthermore, an October 2026 agreement with the Centers for Disease Control and Prevention (CDC) will advance a novel live-attenuated rotavirus vaccine for transdermal delivery, directly targeting distribution challenges in low- and middle-income countries.

From R&D Lab to Commercial Foundry

To meet the anticipated demand across both commercial therapeutics and global health initiatives, Micron has officially transitioned from a research and development laboratory into a commercial manufacturer. The company opened its commercial-scale manufacturing foundry in Alpharetta, Georgia, in 2026, bringing formulation, scale-up, and commercial supply under one roof.

Scaling the production of dissolvable microarrays presents unique operational and regulatory hurdles. The products are classified by the FDA as drug-device combination products, a category that demands rigorous Current Good Manufacturing Practice (cGMP) compliance for both the pharmaceutical formulation and the physical delivery device. Regulatory science for microneedles is still considered an evolving field, requiring companies to navigate complex pre-market approval and new drug application pathways without the benefit of decades of explicit regulatory precedent that exists for traditional syringes.

The Alpharetta facility was funded in part by a Series A3 financing round exceeding $16 million in early 2025, led by J2 Ventures and the Global Health Investment Corporation. The site is designed to produce at least 10 million patch-like devices annually, with architectural and operational blueprints in place to add additional manufacturing lines in the United States over the next three years.

"Micron Biomedical has built strong demand for its dissolvable microarray platform, supported by compelling clinical evidence of its safety and efficacy and commercial-scale manufacturing foundry capabilities designed to expand with growing demand," Dr. Subramony stated regarding his new role. "The next step is translating this innovative platform into commercially viable products that patients can administer at home, that reduce cold-chain requirements and generate significantly less plastic and sharps waste than traditional injections. I'm excited to join Micron at this pivotal stage and help bring a new generation of more accessible, convenient and sustainable vaccines and therapeutics to patients worldwide."

As the biotechnology sector increasingly looks beyond the needle, Micron's aggressive manufacturing expansion and strategic executive appointments position the company to capitalize on a growing demand for patient-centric delivery systems. With a pipeline spanning infectious diseases, dermatology, pain management, and weight loss, the successful commercialization of this microarray platform could soon redefine the standard of care for millions of patients globally.